TB Treatment Regimen in Chronic Kidney Disease

Drug-Susceptible TB: Standard Regimen with Renal Adjustments

The American Thoracic Society recommends using the standard 2HRZE/4HR regimen with dose adjustments only for ethambutol and streptomycin when GFR falls below 30 mL/min, while rifampicin, isoniazid, and pyrazinamide can be given at standard doses regardless of renal function 1, 2
Rifampicin can be given at standard dose (typically 600 mg daily for adults >50 kg) regardless of GFR or dialysis status 1
Isoniazid can be given at standard dose (typically 300 mg daily) regardless of renal function 1
Pyrazinamide can be given at standard dose regardless of renal function 1
Ethambutol requires reduced dose and serum concentration monitoring when GFR <30 mL/min due to risk of optic neuritis from drug accumulation 1
Streptomycin requires reduced dose and serum concentration monitoring in renal impairment; avoid if possible due to ototoxicity risk 1

Administer all TB medications after dialysis sessions to prevent premature drug removal, particularly for pyrazinamide and cycloserine which are dialyzable 3, 2
Rifampicin and isoniazid are not significantly removed by dialysis and can be given at any time, but post-dialysis dosing facilitates directly observed therapy 3, 2

Moxifloxacin 400 mg once daily requires NO dose adjustment for any level of renal impairment, including dialysis patients, making it the superior choice for CKD patients with MDR-TB 2
Moxifloxacin undergoes primarily hepatic metabolism rather than renal clearance 2
Moxifloxacin is not significantly removed by hemodialysis or peritoneal dialysis 2
Moxifloxacin can be administered at any time relative to dialysis 2
Levofloxacin requires reduced dose and serum concentration monitoring in renal impairment; avoid if possible due to ototoxicity risk 2, 4, 5

Build regimens using WHO Group A drugs (bedaquiline, moxifloxacin, linezolid) plus at least one Group B drug (clofazimine, cycloserine/terizidone), prioritizing medications that don't require renal dose adjustment 6, 7, 8
Group A drugs (use all three if possible): Levofloxacin/moxifloxacin (prefer moxifloxacin in CKD), bedaquiline, linezolid 6, 7, 8
Group B drugs (add at least one): Clofazimine, cycloserine/terizidone 6, 7, 8
Avoid kanamycin and capreomycin in MDR-TB regimens due to nephrotoxicity and ototoxicity 9, 7
Total treatment duration: 18-20 months for longer MDR-TB regimens 9, 7

Never assume "normal" serum creatinine indicates adequate renal function—muscle mass decline in CKD patients masks severe renal impairment; always calculate GFR 4, 5
Do not administer fluoroquinolones within 2 hours of antacids or medications containing divalent cations (calcium, magnesium, iron, aluminum) as these drastically reduce bioavailability 2, 4
Avoid aminoglycosides (amikacin, streptomycin) when possible in severe CKD due to nephrotoxicity and ototoxicity; if used, require dose adjustment and serum concentration monitoring 9, 7
Monitor liver function weekly for first 2 weeks, then every 2 weeks during initial phase 1
Consider therapeutic drug monitoring for rifampicin if poor response suggests malabsorption or under-dosing 10
Assess renal function periodically during treatment as CKD may progress 4, 5

All first-line drugs can be used with appropriate adjustments in dialysis patients 1, 3
Post-dialysis administration prevents premature drug removal and facilitates directly observed therapy in dialysis patients 3, 2
Moxifloxacin offers significant practical advantage over levofloxacin by not requiring dose adjustment or specific timing in dialysis patients 2

In patients whose hemoglobin is normal, iron supplementation should be stopped; iron is indicated only for documented iron deficiency (transferrin saturation < 15 % or ferritin < 30 ng/mL) or functional iron deficiency during erythropoiesis‑stimulating agent therapy. [National Comprehensive Cancer Network (NCCN) 2012] 11

The World Health Organization (WHO) gives a strong recommendation to include linezolid as a Group A drug in MDR/RR‑TB treatment regimens despite its risk of anemia. [WHO 2021] 12
When anemia occurs during linezolid therapy, the preferred strategy is to reduce the dose to 300 mg daily rather than add iron supplementation. [International Journal of Infectious Diseases 2023] 13
The standard linezolid dosage is 600 mg daily for 26 weeks; dose reduction to 300 mg is acceptable to mitigate hematologic toxicity. [International Journal of Infectious Diseases 2023] 13

Baseline and regular complete blood‑count (CBC) monitoring are advised to detect linezolid‑induced cytopenias early. [American Journal of Respiratory and Critical Care Medicine 2017] 14
If hemoglobin drops below 7 g/dL or platelets fall below 75 000 mm³, clinicians should consider linezolid dose reduction or an alternative regimen. [International Journal of Infectious Diseases 2023] 15

The WHO strongly recommends inclusion of levofloxacin (or moxifloxacin) in MDR/RR‑TB regimens. When iron supplementation is required, administer levofloxacin at least 2 hours apart from iron to avoid chelation and preserve fluoroquinolone efficacy. [WHO 2021] 12